Trial · NCT01753713
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Arm 1: Progression Free Survival (PFS) | Anti-angiogenic Therapy Naive Patients | 0 | Participants | ||
| Arm 1: Progression Free Survival (PFS) | Anti-angiogenic Therapy Patients | 0 | Participants | ||
| Arm 2: Determine Median Time to Progression | Anti-angiogenic Therapy Naive Patients | 1.8 | 95% Confidence Interval 1.3 to 2.8 | Months | |
| Arm 2: Determine Median Time to Progression | Anti-angiogenic Therapy Patients | 1.8 | 95% Confidence Interval 0.7 to 1.8 | Months | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Naive Patients | Grade 1 | 217 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Patients | Grade 1 | 119 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Naive Patients | Grade 2 | 109 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Patients | Grade 2 | 85 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Naive Patients | Grade 3 | 55 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Patients | Grade 3 | 40 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Naive Patients | Grade 4 | 2 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Patients | Grade 4 | 5 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Naive Patients | Grade 5 | 1 | Events | |
| Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Anti-angiogenic Therapy Patients | Grade 5 | 2 | Events | |
| Objective Response Rate Using Modified Revised Assessment in Neuro-Oncology (RANO) Criteria | Anti-angiogenic Therapy Naive Patients | Complete Response | 0 | Participants | |
| Objective Response Rate Using Modified Revised Assessment in Neuro-Oncology (RANO) Criteria | Anti-angiogenic Therapy Patients | Complete Response | 0 | Participants | |
| Objective Response Rate Using Modified Revised Assessment in Neuro-Oncology (RANO) Criteria | Anti-angiogenic Therapy Naive Patients | Progressive Disease | 8 | Participants | |
| Objective Response Rate Using Modified Revised Assessment in Neuro-Oncology (RANO) Criteria | Anti-angiogenic Therapy Patients | Progressive Disease | 8 | Participants | |
| Objective Response Rate Using Modified Revised Assessment in Neuro-Oncology (RANO) Criteria | Anti-angiogenic Therapy Naive Patients | Stable Disease | 3 | Participants | |
| Objective Response Rate Using Modified Revised Assessment in Neuro-Oncology (RANO) Criteria | Anti-angiogenic Therapy Patients | Stable Disease | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01753713/results